LSUHSCORS PRESENTS:

Research Billing in EPIC

May 1, 2024

Brianne Voros, MS, CCRP

Email: bvoros@lsuhsc.edu

Objectives

- Discuss the importance of the MCA in the context of Research Billing Compliance
- Review Linking to Research Studies in Epic
- Describe the process for Research Billing Review in Epic

Lifecycle of a Clinical Trial



Components of Research Billing in EPIC

- 1. Medicare Coverage Analysis (MCA)
- 2. Standard of Care Processes that affect Research Billing Compliance
- 3. Linking to Research Study in EPIC
- 4. Research Billing Review

What is a Medicare Coverage Analysis?

Analysis required for all clinical trials involving tests, procedures, and interventions associated with a clinical trial that are invoiced to third party payers (i.e., Sponsors) to determine what costs, if any, can be covered by Medicare.

The MCA is one of the most useful documents for building a clinical trial budget and ensuring clinical trial billing compliance.

LSUHSC CTO Training - Medicare Coverage Analysis for Clinical Research

Understanding the MCA ...and Why It Is IMPORTANT

- The Principal Investigator (PI) has the ultimate responsibility for achieving research billing compliance..... but the full support of the study team is needed to do so successfully.
- The PI has primary responsibility to understand and comply with rules for billing Medicare, Medicaid and third-party payors for services, drugs, devices, tests and procedures rendered in the clinical research context.
- Other site personnel (including patient service representatives, billers, coders, clinic administrators, etc.) are responsible for working with the Principal Investigator and study team to ensure that services for patients enrolled in research studies are <u>scheduled</u>, coded, billed and documented appropriately.

Risks Associated with Research Billing Non-Compliance

- Billing for services that are already paid by the sponsor (double billing)
- 2. Billing for services promised free in the informed consent
- 3. Billing for services that are for research-purposes only
- 4. Billing for services that are part of a non-qualifying clinical trial and do not qualify for coverage

Federal False Claims Act

- Federal False Claims Act (FCA) establishes liability for anyone who submits a false claim for payment to the government
 Specific intent not required
- False Claims Act applies to clinical research activities and failure to comply with the rules may lead to fines and penalties
- Under the False Claims Act, those who knowingly submit, or cause another person or entity to submit false claims for payment of government funds, are liable for three times the government's damages plus civil penalties of \$10,781 to \$21,563 **per** false claim.
- Study documents and MCA must be aligned to assure compliance with clinical trial billing rules and the regulations that protect human subjects



The 3 C's of Research Billing Compliance

- 1. Coordination of study information across multiple study documents
- 2. Communication of relevant study information to the billing process
- 3. Cooperation among departments and offices that may not usually work together

The 3 C's of Research Billing Compliance

- 1. Information that must be coordinated and communicated to minimize compliance risks
 - What is billable and not billable
 - Who is enrolled in a research study
 - Which services are required by the protocol
- 2. Within an academic medical setting, many different parties are involved in developing study documents that have important information for billing:
 - University/Campus
 - School of Medicine
 - Medical Center
 - Physician Offices
 - Sub-contractors/Private Physician Groups

The PI and SC should be the Protocol EXPERTS for Non-Study Staff



The MCA is our cheat sheet to WHO pays WHAT

Research Billing Terms & Definitions

- **Study related**: A service/procedure that must happen for a research study and occurs after the subject has signed the research consent.
 - Study-related services may bill to insurance (designated as **M** on the MCA)
- Routine Care Costs aka Standard of Care: A study-related service that *also* happens as part of a subject's standard medical care *and* is not promised free from the sponsor is designated as M on the MCA. M services bill to insurance.
 - These costs may include doctor visits, hospital stays, and lab and imaging tests.
- **Research Sponsored (S)**: A study-related service that *only* happens for research, <u>or</u> is promised free from the sponsor (even if it is part of a subject's standard medical care) will be designated as S on the MCA. **S services must bill to the sponsor.**
 - These costs may include the investigational intervention (such as the drug being tested), extra doctor visits, electrocardiograms or blood draws, certain lab and imaging tests, and questionnaires performed solely for research purposes.

MCAs can be simple and easy to understand

S=Paid for by study and cannot be billed to insurance

INV=Invoiceable services paid by study

M=Routine cost in a qualifying clinical trial and can be billed to Medicare

M/S=Routine cost in a qualifying clinical trial and can be billed to Medicare. If not covered by insurance, will be covered by sponsor per Non-SOC below.

X=This is a non-billable item and will not generate a charge.

NC= This is not a billable charge.

			Baseline/		Post							
	CPT Code	MODIFIER	Screening	Surgery Visit	Surgery/	Week 6 ±14	Month 3	Month 6	Month 12	Month 24	Unschedule	
VISIT SCHEDOLE	CFICOUE	TYPE	(-90 days)		Discharge	days	150 days	150 days	100 days	100 days	u	
												COMMENTS
PROTOCOL RELATED ITEMS & SERVICES												
Informed Consent Process			S									
Eligibility Confirmation			S	S								
Demographics			S									
Medical History			S									
Physical Exam			М	M	S	S	S	S	S	S	S	Post Surgery/Discharge, per investigators discretion
Neurological Examination			S	S	S	S	S	S	S	S	S	Post Surgery/Discharge, per investigators discretion
X-ray (AP lateral fley/evt films)	72050		м	M	M	s	s	s	s	s	s	For Surgery Visit, Pre- and post-implant images will be collected using intra-operative fluoroscopy instead of standard x-rays. For Post
A ruy (Al , lateral, nexy ext hints)	72030											Surgery/Discharge Visit, Neutral AP and Lateral X-ray only, per investigator's discretion.
Osteoporosis Assessment			S									
CT scan	72125		м		м				5	\$		CT scan optional to rule out any bony abnormalities. For 12m and 24m, sagittal and coronal reconstructions are required
MRI	72156		м									MRI required for all patients, unless Inclusion #2b is determined using x- rays or CT
Surgical Procedure				м								For investigational portion of surgery, device is provided by sponsor.
Pregnancy Test	81025		м									Females of childbearing potential only.
Nicotine Intake			S			S	S	S	S	S		
VAS pain			S			S	S	S	S	S		
NDI			S			S	S	S	S	S		
SF-12 and EQ-5D-5L			S			S	S	S	S	S		
Satisfaction Survey									S	S		
Employment Status			S			S	S	S	S	S		
Adverse event assessment				S	S	S	S	S	S	S	5	
Concomitant medications			S	S	S	S	S	S	S	S	S	

... or MCAs can be very complex

												Tre	atment																Follo	w Up				
	Screening																														Comments			
	1@21Days	Treatmen	nt Cycles d	-4.4 Cycl	les @56D	895																				Long Ter	m Safety	Follow-up	p Visits				EOS	Competers
	Screening	C1D1	C1D7	C1D14	C1D28	C1D42	C1056'	C2D1	C2D7	C2D14	C2D28	C2D42	C2D56'	C3D1	C3D7	C3D14 C	3D28	C3D42	C3D56"	C4D1	C4D7	C4D14	C4D28	C4D42	C4D56/6	Long Ter	Long Te	r Long Tei	Long Ter	Long Ter	Long Ter	Long Ter	EOS M	
Informed Consent	\$00										_						-				_		<u> </u>			<u> </u>	<u> </u>							This is not a billable item or service.
Indusion/Exclusion Criteria	SIXQ						-	_			_												<u> </u>	_			<u> </u>							This is not a billable item or service.
characteristics	500																																	This is not a billable item or service.
Medical History	500				_							_		_	_		-	_	_		_					-	-							This is not a billable item or service.
Prior And Concomitant Medications	5(00)	S(X)	500	5(X)	S(X)	5(00)	S(X)	S(X)	500	S(X)	S(X)	500	S(X)	500	5(X)	S(X)	500	5(X)	S(X)	500	S(X)	S(X)	5(00)	S(X)	S(X)	5(X)	S(X)	5(00)	5(X)	S(X)	500	5(X)	5(X)	This is not a billable item or service.
ECOG Performance Status	\$00	S(X)					\$(X)	SIX					S(X)	500					SDG	\$00					SDO	\$00	SIXI	\$00	\$(X)	SIX	\$00	S(X)	\${X}	This is not a billable item or service.
Height, Weight	\$(0)	S(X)					S(X)	S(X)					S(X)	SDO					S(X)	\$00					S(X)	5(X)	S(X)	\$00	S(X)	S(X)	500	S(X)	S(X)	This is not a billable item or service.
Vital Sign Measurement	\$00	65(X)					S(X)	65(X)					S(X)	65(00)					S(X)	65(00)					SDO	S(X)	S(X)	500	S(X)	S(X)	\$00	5(X)	5(X)	This is not a billable item or service.
flood and the second																																		A conventional care reference for this item could not be found following review of UpToDate and NCCN
- swa (cat, eages)	6				_						_				_	-					_			_			-	-			_			doweries. Therefore, and items considered research related and should be paid for by the sponsor.
											_	-		-	_	-	-	_	-				-	_		-								
Physical Examination	MI	MI					ML	MI					MI	M1					MI	M1					M1	M1	M1	M1	ML	MI	MI	MI	ML	A physical term appears reasonable and necessary at this Research for the dirical management of the pattern for eler to accurate the pattern' disease transition, and was to describe the direct of 2019 ColOrding To the NCCO solidations for Neuroscience and Advenait Tumors (v4.2021), during follow-up the term is recommended every 12-34 weeks for 2 years (NCCO 4) and every 6-34 weeks for patterns with Novie terms is recommended every 13-34 weeks for 2 years (NCCO 4) and every 6-34 weeks for patterns with Novie terms in second and the NCCO 4000 and the second and years and the second and years and years and the second and years and the second and years and the second and years and the years and years and the second and years
- E&M-EST, PATIENT-LVL IV (CPT-																																		
99214)	M1	M1					M1	M1					M1	M1					M1	M1			-		M1	M1	M1	M1	M1	M1	M1	M1	M1	
+ E&M+EST, PATIENT+LVL V (CPT+																						/	-1											
99215)	M1	M1					M1	M1					M1	M1					M1	M1	/	-	1		M1	M1	M1	M1	M1	M1	M1	M1	M1	
Histopathology ⁴	SIXQ		-											-	-		-	-		/		1	-1	-		-						_	-	This is not a billable item of service.
Pretry and Test For WOCRP	COMO	sume					00000	COMP.					conte	same				-	/		/	_	-	4	50000	sume	SUMPO	50000	suma	SUMO	some	custo	come	Therefore, this item should be considered research related and paid for by the more set.
 URINE PREGNANCY TEST (CPT- 	STURY	3(100)	-				-3(INO)	30044)					-(INV)	SUMM	-		-	/		/		1	/	1-	3(INV)	SUNW	SUW)	S(INV)	S(INV)	3000)	S(INV)	JUNO)	(INV)	mercrore, one new shows be considered research related and para for by the sponsor.
81025)	SUNVI	SINO					SUNVI	SUNVA					SUNA	SONV		/	_	~	/		/	_	-	1	SUNVI	SUNA	SUM	SUNVI	SUNVI	SUNVA	SUNVI	SUNVI	SUNVA	
- HOG QUANTITATIVE (CPT-84702)	S(INV)	S(INV)					S(INV)	S(INV)					S(INV)	S(INV)	/		~	/		/	-	-	/		S(INV)	S(INV)	S(INV)	S(INV)	S(INV)	S(INV)	S(INV)	S(INV)	S(INV)	
Adverse Event Collection		S(X)	\$00	S(X)	S(X)	500	5(X)	S(X)	500	S(X)	SDO	SIX	S(X)	1	-	1	_		/	-	/	_		1	SDO	5(X)	S(X)	\$00	5(X)	S(X)	500	5(X)	5(X)	This is not a billable item or service.
												U	/	-	/		_	/		/	-	-	/	1										212Pb-DOTAMTATE will be provided by the sponsor (Protocol, p. 32). It should therefore be considered
212pb-DOTAMTATE (IV)		NB(NC)						NB(NC)				/		/		-	/		/	-	-	/		-1										research-related.
											/		/	-	/		_	/	-	/	_	_	/											This item is required for the provision of IV medication used in the study. Coverage is supported by NCD
21200-DOTAMITATE Administration		mı						mi	-			\sim	-	/	-	-	/		/	_	-	/		/	1—	-	<u> </u>							3101.
ADD/L HOUR (CPT-96366)		M						1		-	-		/	-	-			/		/	_		/		7									
+ HC IV INFUSION, THERAPY - UP TO									-		anc	~	-	1	-	1	/		/	-	-	/		/	-1-									
ONE HOUR (CPT-96365)		M1				-	atio	ms		Insu	~		/	-	-	/		/		/	_		\sim	-	7									
					1	osigi	nati	oati	jeny	/		/	-	1	/	-	/		/	_	-	/		/	-17									This premedication is required by the protocol to be taken with the study drug to prevent infusion-related
Pre-AA Anti-emetic Medications*		M1		illin	ne D	este	UI tC	Pac		× -	/	-	1	_	-	/		/	-	1	/		/	-	1	L								reactions (Protocol, p. 6). Coverage is supported by NCD 310.1.
			1	Billi	10	- 18	SIL	co	onsy	~		/	_	-	/		/		-	/		\sim		/	-	1								This premedication is required by the protocol to be taken with the study drug to minimize kidney toxicity
Amino Acids		M1				1	aill t	90 24	-		/	-	-	/		/		/	-	-	\sim		/	-	-	4	<u> </u>	-						(Protocol, p. 6). Coverage is supported by NCD 310.1.
AA Infusion		- MO		M	/	- 1	BII	ailli	able	/		/	_	-	/		/	_	-	/		/		1	_	1								This item is required for the provision of ty medications used in the study. Coverage is supported by NCD
- WORKING READY - EA				1-	-	-	tout	F BIII	/		/	_	-	/		/		-	_	-	/	-	1	-	-	λ^{-}	-							3404.
ADD'L HOUR (CPT-96366)		M1		15	/	_	1140	/		/	-	/	_	-			/	-	-	/		/		/	/	1								
+ HC IV INFUSION, THERAPY + UP TO					IR	1	1	-	- 3	ions	1	TR	-	600	sen	/		/	_	-	\sim		/	_	-	1								
ONE HOUR (CPT-95365)		M1		10	10	_	-	-1	anat	10.	-100	June	-00	100	-	Vbr	/	-	_	/		/	_	-	/	1.								
				4	_	-	-	Desi	0	dpr	000	FOI	me		he s		10	-	- 25	01.	/		/	_	_	\neg	£							This item is for submission of a blood sample to a central lab for analysis (Protocol, p. 39). Therefore, it
PK Blood Samples"		55(50)		\rightarrow	1-	or	ting	-	oed	eu	nin	Inio	100	by y	-	aillan		- ST	0011-	-		/	-	-	/	1	1		-					should be paid for by the sponsor.
DX Living Collections		1000			Cul	ppu	-	AST	-	Afre	e	all	940	-	tely	0	av t	hes	-		/	ons	0	/		\sim	٦							I his item is for submission of a unite sample to a central lab for analysis (Protocol, p. 39). Therefore, it should be paid for by the spanner.
PR OTHE CONCLUSION		39301			-13-1-	-	1	1	mise	au -	100	n Por	60	naro	-	for	1			-1	e SI	por	_	-	/		7-	-	-					produce para for of the sponton.
					Alat	5 2 2 2 2		PLC B	voice	harg	ervic e-th toft e car	e, No his ite he Re e per	esea rforr	ned f	tem	afety	and	pair	ener	ate a	cha	rge												The tent is provided at concerning to serve as a bandhors and during produced to motion for bandhors the index comparisons on the line (bots specific (b) and (b) concerning at concerning during the interface, and during the herbit concerning and an appointed by NK2 302.1. A second gradient of the second concerning and an appointed by NK2 202. In concerning the interface of the second concerning and the second gradient of the second gradient of the second concerning the second gradient of the second concerning the second gradient concerning 2023 (C) CONTRATE, is concerned and an art inference could not be consider to second concerning the second concerning the second concerning the second concerning and second concerning a second concerning and appointed on appointed on the second concerning and appointed on participation of the second concerning and appointed on appointed on the second concerning and appointed on participation of the second concerning and appointed on participation of the second concerning and concerning
Clinical Chemistry	M1	M1		M1	M1	1 EM	JR_		Ikc	-	nut	/	Lilla	ple.		M1	M1	M1	M1	M1		M1	M1	M1	M1	M1	S	S	s	5	s	s	s	mo follow-up period.
COMPREHENSIVE METABOLIC PAN							CIRC	-	te	end	/	non	Unite																					
14 CMP (CPT-80053)	M1	M1		M1	M1	MI	SI	/	15	-	e an	Inc	- 11	M1		M1	MI	M1	M1	M1	_	MI	M1	M1	M1	M1	S	S	S	s	s	s	s	
							100	-	-	THIS	-	-																						
							1×1																											This term is provided at screening to sarve as a baseline and during the atternet to monotor for the streening method completions such as indiced from the blood will be atternet to the streening. Completions and and only the stree blood of the streening of the streening to a streening completions and and streening the streening of the streening the streening that and as all According the block conclusions plot desires for the streening streening streening streening completions and and streening s
i la contra																																		Therefore, this item should be considered research-related and paid for by the sponsor during the 6 mo - 24
Hematology	M1	M1	_	M1	M1	M1	M1	M1		M1	M1	M1	M1	M1		M1	M1	M1	M1	M1		M1	M1	M1	M1	M1	S	S	S	5	S	S	S	mo tollow-up period.
COMPETER W/ACTOM DIFF					M		AU						M	141				A41						M		-								
														in a				ma										-				-		Coverage for this item is limited by NCD 190.17. Therefore, this item should be considered research-related
Coagulation/	S(INV)																																	and paid for by the sponsor.
- PROTHROMBIN TIME (CPT-85610)	S(INV)																																	
																	T																	Coverage of this item is limited by NCD 210.7. Therefore, it should be considered research-related and paid
Virus Serology (HIV)	S		_								_				_																	_	_	for by the sponsor.
 HIV-1 DTMA CLUAL BY PCK (CPT- 075.06) 																																		
	0		-								_		-	-	_	-	-	_	-		-										-	-		Coversee of this item is limited by NCD 210.6. Therefore, it should be considered research-related and naid
Virus Serology (Hepatitis B)	s																																	for by the sponsor.

Lessons Learned

Never assume that RESEARCH means that everything required by the protocol is FREE

Let the normal processes that are currently in place for nonresearch patients continue to function for your research patients (i.e. prior authorizations, scheduling, etc.)

Utilize the current workflows of the clinic/hospital/support staff to implement the clinical trial.

How do we IDENTIFY Patients in EPIC as Enrolled in Research?

Linking Patient to the Research Study

y Mainten	ance 🏠 P	atient Station	∔ ≣ Patient Lists	🔎 My Reports 🛛 🛱 Appt	s 🔣 Snapboard	Resear	ch Billing F	Review 🌜 Tele	phone Call 🍕	• Encounter	📑 ED Track Board	💽 Media M	1	🚱 Research Studies
(Ctrl+1)×												-	_
$\leftarrow \rightarrow$	SnapShot	Chart Review	w Order Inquiry	y Review Flowsheets	Results Review	Allergies	History	Problem List	Demograph	ics Letters	Research Studies			
Resea	rch Stu	dies												
Tulane	Asthma S	tudy 🕂 Ad	J 3											
Recei	nt													
Tulan	e Asthma S	Study [10012]												

- 1. Click on the Research Studies button in the main toolbar.
- 2. Search for and select your patient to open their chart.
- 3. Within the Research Studies activity, search for the study in the Add study search field.

Linking Patient to the Research Study

lesearch Studies	⑦ ~
Study List	
Tulane Asthma Study	
Participant Details Status Status Effective Date Enrolled: Other I1/8/2024 Active Start Date Active End Date I1/8/2024 Participant ID I234567 Patient-Specific Coordinators Comments B D D D D 2 + Insert SmartText ← → = 0	Study Details Study Type Study Code IRB# NCT# Interventional 10012 102 00704495 Description Tulane Medical Center is participating in a study of the efficacy of asthma treatment and control in patients currently being treated with a leukotriene modulator and/or sympathonimetic agents but are not using inhaled steroids. Patients in this study may be receiving a study medication or a placebo. If you have any patient care concerns potentially related to study, please contact the study team at x5- S555. We Minvestigator Research, MD Principal Investigator Patient-Facing Area of Research Lungs & Breathing Links Clinical Trial Info ●

- 4. Search for and select an active association status, such as In Screening, Consented, or one of the Enrolled options. Once selected, the Status Effective Date will auto populate with today's date. If you need to back chart (chart for events that happened in the past), change the Status Effective Date and the Active Start Date will automatically adjust.
- 5. Enter a participant ID if the patient's name is not used in the study and only an ID number.
- 6. Click Accept to save your changes.

Research Association Status Definitions

Pre-Consent

- Identified subject is identified as meeting prescreening criteria but has not been approached
- Interested subject has been approached to participate but has not signed consent form
- **Declined** *subject is not interested in participating*

After Consent

- In Screening subject has consented to participate but has not completed screening phase
- **Consented** subject has consented to participate but has not started treatment
- Enrolled Treatment Phase subject is on active treatment
- Enrolled Follow Up Phase subject is still on trial but has completed treatment phase and in follow up
- Withdrawn
- Completed subject has completed all study visits and is no longer enrolled in trial

Linking Patient to the Research Study

Monique-RC Bell	Snapshot Chart Review Order Inquiry Review Flowsheets Results Review Allergies History Problem List Demographics Letters Research Studies	र १ २
MRN: 20032978 Language: English Code: Not on file (has ACP docs) Search COVID-19 Vaccine: Unknown Solation: None Research Participant Core Taam: No PCP	Participant Details Additional Info Past Updates Status Status	⊕2 Study Details Study Type Study Code IRB# NCT# Interventional 10012 102 00704495 Description Tulane Medical Center is participating in a study of the efficacy of asthma treatment and control in patients currently being treated with a leukotiene modulator and/or sympathomimed: agents but are not using inihald steadois. Palents in this study may be receiving a study medication or a placebo. If you have any patient care concerns potentially related to study, please contact the study team at x5-5555.
Allergies: Pollen Extracts	台 Study Calendar No study visits	MR Md Investigator Research, MD Principal Investigator Patient-Facing Area of Research
Neight - Scale: 90.7 kg (200 lb) >7 days 3MI:		Lunks Clinical Trial Info ↑ ⑦ Documentation ≪ Adverse Events I Data Capture ☆ Tasks

- 7. Notice a Research Participant banner will appear on the Storyboard. This will alert every provider that views the chart of the patient's participation in a research study.
- 8. You will be able to click on Participant Details hyperlink to view the study report, which will display study details, linked encounters and linked orders

Link Encounter to Study When in an Encounter

- 1. Click on the Research Studies button in the main toolbar.
- 2. Search for and select your patient to open their chart.
- 3. Within the Research Studies activity, search for the study in the Add study search field.



Link Upcoming Visits to Studies via Appointment Desk

- 1. Click **Appts** on your main toolbar.
- 2. Look up your patient and click Accept.
- 3. Right-click the upcoming appointment.
- 4. Select **Link to Research Study** to confirm association or to link the appointment to the research study.
- Click ★ Close when all updates for the encounter are complete.

Link Upcoming Visits to Studies via Appointment Desk

Epic - ChatReview @3	tudy Maintenance 🚛 Patier	Station EPatient Li	sts 🔎 My Reports 🔒 Appts 🍞	apbos	erd 🖉 Research Billing Review	w 🕻 Telephone	Call 9, Encounti	er. 📕 ED Track Board	🗟 Nedia Manager 🔗 R	esearch Studie
🖾 O 🖴 🗄 Reports	Alas, Na	te-RC	×							
	Appt Desk	esk								
Nate-RC Alas Male, 68 y.o., 04/17/1955 608-555-7972 MRN: 20032654	Book It ∳ One Ck	s • ¥ ⊻ukin ∰ y (Edit +) C (68 yrs)	Bequest + 🔋 Reports + 🛊 Pab	ant Optio	gs • 🖶 Printing • 🐑 Form 1 Registration Status	Reprints	la.	Emi		^
Pt Ver Status: Ver PRIVATE: None COVID-19 Vaccine: Unknown	2880 Madrid Dr Verona WI 53593	((())))	4/17/1955 SSN 159-24-1237 Logal Name Alas, Nate-RC		Ver Preferred Language English Needs Interpreter? No	Hom 608- Worl	e 555-7972	Prev	ontive Care	
Research Participant			Check In		2.702					_
My LCMC Health: Inactive	Guarantor Accor	unts	Check Out							
Diana McQueenie, MD PCP - General	Account Name Alas,Nate-Rc	Acct V	er Stal Reschedule Cancel/Reschedule		Serv Area SBO	Type P/F	Fin Class SELF	Balance 0.00	Acct Status	
COVERAGE & FINANCIAL INFO Guarantor: P/F - Self (+1) Self-Pay Bal Due: \$0.00	Account Name	Acct V	or Stat Change Appointment or Stat Edit Appointment Notes	ser	Serv Area	Туре	Fin Class	Balance	Acct Status	
NO SHOWS 0% All departments	Euture East CSN	Encounter Date	Edit Appointment Info Time Copy into Book II.		Provider	Appointment	Department	Appt Notes	ORD R. Rtt Pro	cedure
CCN Insurance: None	3 ^{p05836}	1/9/2024 Tue	9 00 Order Entry Order Review Link Requests	т	Nurse Family Medicine [E400000]	UMCNO ME	D CLN ACB	annual exam		
			Link Research Study Expand Reg Appointment Conta Messace	4						

Reports for Linking Upcoming Visits to Studies

	LCMC ES Appt Search for Research Coordinators								
	Workbench Template 100935	Upcoming Appo	intments (ALPHAM	IEDIX)					
Description Reports created from For example, it may b research study.	this template search for appointments matching the criteria specified. e used to find all appointments for patients enrolled in a particular	Detail List Explore	Research Studies 🌵 Encounter	Eink to Research Study	Prov/Res	Appt Status	Visit Type	Linked Study Code	Linked Start Date
		Linted Fortopurt is	The Date Time	Apr		rippi olutio	non type	Linita olady oode	Linited oftant Date
	LONG ES Aust Second for Bernard Constitution			EJGH OP ONCOLOGY	EJGH OP ONCOLOGY CHAIR 3	Sch	INFUSION TX		
н 14	EGWIC ES Approveron for Research Coordinators			EJGH OP ONCOLOGY	EJGH OP ONCOLOGY	Sch	INFUSION TX		
* ro	Upcoming Appointments			EJGH OP ONCOLOGY	EJGH OP ONCOLOGY FAST TRACK CHAIR 1	Sch	ONCOLOGY LAB		
* 70	Upcoming Appointments (ALPHAMEDIX)			EJGH OP ONCOLOGY	EJGH OP ONCOLOGY FAST TRACK CHAIR 2	Sch	INFUSION TX		
* 7.	Upcoming Appointments (CAMURUS)			EJGH OP ONCOLOGY	EJGH OP ONCOLOGY INFUSION BED 2	Sch	CALCULATED INFUSION 1	ALPHAMEDIX-02	11/08/23
* 70	Upcoming Appointments (CRINETICS)			EJGH OP ONCOLOGY	EJGH OP ONCOLOGY INFUSION BED 1	Sch	CALCULATED INFUSION 1	ALPHAMEDIX-02	01/08/24
* 7.	Upcoming Appointments (FUSE)	,		B EJGH OP ONCOLOGY	EJGH OP ONCOLOGY INFUSION BED 2	Sch	CALCULATED INFUSION 1	ALPHAMEDIX-02	01/22/24
* 7.	Upcoming Appointments (Neulasta)								
* 7	Upcoming Appointments (REFINE)								

- Search in Reporting Workbench for LCMC ES Appt Search for Research Coodinators.
- Modify report with Study Code and Save Report as Favorite.
- Select visits to be linked and Click Link to Research Study.
- Can be used to link Past or Upcoming Appointments Reach out to me if you need additional guidance on setting these up.

Linking Orders to Research Study When in an Encounter

Orders Visit Checklist This Visit			Op <u>t</u> ions •	D
⊘ Dx Association 💉 Edit Multiple 💿 Estimate Options ▾ 📮		R Providers		
		CC Results		
U This patient has active treatment/therapy plans.		👌 New Interactions		
🖹 Signed This Visit 🛛 🗧 🖇		👉 Create Panel		
🟠 Unsigned – Outpatient Orders (Incl Rx)	· · · ·	Routing		
CBC with Differential - Please order CBC unless diff clinically indicated ^O o ■ Expected: 4/30/2024, Expires: 4/30/2025, Lab Collect, STAT, When auto diff is abnormal, we will reflex to order Manual Differential	C le t	Financial	_	
Comprehensive Metabolic Panel		Research Association	י	
Expected: 4/30/2024 Approximate, Expires: 4/30/2025, Lab Collect, STAT	2	Show signed orders i	in orders cart	
CL Abdomen Pelvis w wo Contrast ⊗ Expected: 5/11/2024, Expires: 4/30/2025, Routine, Ancillary Performed, Reason for Exam: Metastatic disease evaluation		Show medications do	ocumented this	s vis
CT Chest with Contrast				
			Associate F	₹es

- 1. At the top of the Orders Panel, select Options.
- 2. Then Click Research Association.
- 3. In pop up, Select the check box next to the Order to Associate under the applicable study.

Associate Research Studies			×
	UMC	19-174 El ⁰	3H Crinetics
CBC with Differential - Please order CBC unles			
Comprehensive Metabolic Panel			
CT Abdomen Pelvis w wo Contrast			
CT Chest with Contrast			
~	<u>A</u> ccept		× <u>C</u> ancel
~	<u>A</u> ccept		X Cancel

Linking Patient to the Research Study

R	esearch St	udie	25			
	☐ ⊻iew Study L	ist				
EJ	GH ALPHAM	1EDI)	<-02			
	🛊 Participan	t Deta	ails 🖉 8		Additional Info	Past Updates
	Status Enrolled: Trea	atmen	Status Effective Date t Phase 11/14/2023			
	Active Start Da 11/9/2023	ate A	active End Date			
	Participant ID					
	Patient-Specif	ic Coo	rdinators			
	CR Con	nie Ro	maine, RN Brianne Voros			
	Comments	_				
		_				
	🛗 Study Cale	endar				Hide Past
	Date	Enco	punter Type	Dept	Provider	
	Past					
	11/10/2023	9	HOV - HOV - Completed	EJGH OP ULTRASOUND	EJGH US OP 3	:•
	11/10/2023	9	HOV - HOV - Completed	EJGH CARD TESTING	LCMC CV EJGH CARD TEST ECG	÷ -
	11/13/2023		CT CHEST WITH CONTRAST Visit - Canceled	EJGH OP CT SCAN	EJGH CT OP 1	÷ -
	11/13/2023		CT ABDOMEN PELVIS WOW CONTRAST Visit - Canceled	EJGH OP CT SCAN	EJGH CT OP 1	÷ -
	11/13/2023		Rare Cancer Established Patient Visit - Completed	ZZZEJGH YEN RARE CANCR	Mary Alice Hobbs-Maluccio, MD	÷
	11/13/2023	9	HOV - HOV - Completed	EJGH MRI	EJGH MRI 3T	÷ •
	11/14/2023	÷.	Research Initial Evaluation Visit - Completed	ZZZEJGH YEN RARE CANCR	Mary Alice Hobbs-Maluccio, MD	÷ •
	11/14/2023		Infusion, 90 Minutes Visit - Completed	EJGH OP ONCOLOGY	Sherry Sherwood, RN	: •

Once linking begins, you will be able to click on the **Participant Details** hyperlink to view the study report, which will display study details, linked encounters and linked orders in the Study Calendar.

Professional Billing Charges

- Currently, Professional Billing Charges are billed outside of Epic through ACS (in most cases)
- Therefore, these charges are not captured in Epic. Because these charges may be reimbursed by the sponsor, some important safeguards are required to flag research patients when the billing report is sent to ACS.

This can be accomplished with the diagnosis code **Z00.6**: Examination of participant in clinical trial

This will FLAG the patient as enrolled in a clinical trial and prompt ACS to reach out to the Study Coordinator.

CMS – Z00.6 and Q0/Q1 Modifiers

CMS requires that the following diagnosis code be used on Medicare research claims to identify Medicare patients who are participating in a **Qualifying Trial**:

• Diagnosis code **200.6: Examination of participant in clinical trial**

In addition, the claims must include one of the following modifiers to differentiate between routine and investigational clinical services:

- **Q0** Investigational clinical service provided in a clinical research study that is in an approved clinical research study.
- **Q1** Routine clinical service provided in a clinical research study that is in an approved clinical research study.

Coding Office Visits with Modifiers

Wrap-Up	?
🛐 Images 🔊 Benefits Inguiry 🤚 Dictations 👻 🔨 Open Orders 🎆 Care Teams 🖾 Links 👻 🔊 Preview/Print AVS 🗮 FC Checklist More 🗸	
Patient Instructions Follow-up Communications Review Visit Diagnoses LOS Charge Capture	8-
a Level of Service	
	£.
RET1 RET2 RET3 RET4 RET5	-
IPREV18 IPREV40 IPREV65+ PPREV18 PPREV40	
PPREV65+ TCM 14 Day TCM 7 Day No Fee	
LOS: PR OFFICE OUTPATIENT NEW 45 MINUTES [99204]	4
Modifiers: +	
Additional E/M codes: Click to Add	
Billing area:	

- Q0 Investigational clinical service provided in a clinical research study that is in an approved clinical research study.
- Q1 Routine clinical service provided in a clinical research study that is in an approved clinical research study.

Best Practice

	BestPractice Advisory -	
🗓 🛛 DID YOU ADI	D Z00.6 TO YOUR VISIT DIAGNOSES?	
	 This patient is enrolled in a clinical trial. Please consider: Linking patient to research study Ensuring that all orders are linked to the research study before signing view 	sit.
Click HERE to provide	feedback on this BPA	
Remove	Keep Check with your Study Coordinator S Expires: 5/9/2020, Routine, Lab Collect	
See comments		
		✓ Accept

Putting it ALL together

Research Billing Review Process

All charges linked to patients enrolled in a research study in Epic are flagged and reviewed to make sure they're billed appropriately through the Research Billing Review Process.

Each charge associated with a research patient falls into one of three buckets:

- **Non-research related**. These charges are billed to the patient or their insurance.
- **Research-related, bill to the study**. These are research charges that will be billed to the study or study sponsor.
- **Research-related, bill to the patient**. These are research-related charges that are billed to and paid by the patient or their insurance.

Research Billing Review Process

🛱 Calculated Infusion 1 Visit											
04/30/24		Study-Related			Radiation/Oncology Series DNB (DNB Error) BLUE CROSS - BLUE CROSS POS				Mark a	✓ s Reviewed	
la Charges 🖓 Encounters										📑 Acco	ount Activities
C					Group by: Revenue 0	Code CPT®/HCP	CS Code Svc Date	Encounter	Review Status	Protocol Day	None Other -
Study-Related - Bill to Study											
🛞 Research Correct All 🛛 🗮 Select All 🖉 Deselect All											
	Study R	Svc Date	Post Date	Code	Procedure		Study Src		sh Amount	Qty	Amount
		04/30/2024	04/30/2024	36415	30000030-HC VENIPUNCTURE				29.50	1	59.00
		04/30/2024	04/30/2024	86316	30280015-HC LABCORP IMMUNOASSAY TUMOR AN	TIGEN QUANT	Ê.		89.50	1	179.00
Study-Related - Bill to Insurance/Patient											
	🛞 Research	Correct All 🛛 🗮 S	Select All 📃 Des	select All							
	Study R	Svc Date	Post Date	Code	Procedure		Study Src			Qty	Amount
		04/30/2024	04/30/2024	2500000	ONDANSETRON HCL (PF) 4 MG/2 ML SOLN		Ê			16	14.75
		04/30/2024	04/30/2024	2500002	DEXAMETHASONE SODIUM PHOS 10 MG/ML SOLN		Ê			10	8.75
		04/30/2024	Pending	2500003	arginine-lysine-sterile water 25-25 mg/mL Soln		Ē			1	1,489.75
Non-Study Charges											
🛞 Research Correct All 🛛 🗮 Select All 🖉 Deselect All											
	Study R	Svc Date	Post Date	Code	Procedure		Study Src			Qty	Amount
		04/30/2024	04/30/2024	96375	26000010-HC INJECTION INTRAVENOUS THERAPEU	FIC/PROPHYLA				2	500.00
		04/30/2024	04/30/2024	96365	26000014-HC INTRAVENOUS INFUSION THERAPEUT	IC/PROPHYLA				1	666.00
		04/30/2024	04/30/2024	96366	26000004-HC INTRAVENOUS INFUSION THERAPEUT	IC/PROPHYLA				4	652.00

Important Takeaways

- 1. Understanding the MCA is the foundation of ensuring compliant research billing
- 2. Linking Patients, Orders, and Encounters on the front end saves a headache on the backend
- 3. Communication with all involved is KEY
- 4. Add Z00.6 diagnosis code with Q0/Q1 modifiers
- 5. Research Billing Non-Compliance jeopardizes our ability to continue doing research. We must work together to ensure that it is done correctly!

Resources

- LSUHSC CTO Training Medicare Coverage Analysis for Clinical Research
- <u>CITI Training Clinical Trial Billing Compliance</u>
- <u>CMS.gov National Coverage Determination (NCD) Routine Costs in Clinical Trials</u>
- HCPCS Modifiers when Billing for Patient Care in Clinical Research Studies

